ravulizumab
Tue, 10 May 2022 13:01:45 -0400
For the treatment of adults and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
Tue, 10 May 2022 13:01:45 -0400
For the treatment of adults and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
80.211.154.110